{
    "clinical_study": {
        "@rank": "53809", 
        "acronym": "Novitas", 
        "arm_group": [
            {
                "arm_group_label": "Case", 
                "description": "Patients with documented (histologically/pathologically confirmed) mBC diagnosis less than or equal to 6 months before registry enrollment with metastatic breast cancer, diagnosis of metastases secondary to breast cancer, date of diagnosis for metastases on or after date of diagnosis for breast cancer who are female gender, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions)."
            }, 
            {
                "arm_group_label": "Control Pool", 
                "description": "Patients with documented mBC diagnosis ICD-9 codes (ICD-9 codes: 174.xx [breast]; 196.xx, 197.xx and 198.xx [secondary malignancies]), diagnosis of metastases secondary to breast cancer, date of diag. for mets on or before date of diag. for breast cancer, actively treated by a MD at a cancer center in the Altos OncoEMR\u2122 system who does not incorporate CTC testing in their management of mBC patients, such that the pt. has no record of CTC use at all (excluding patients who sought consults or second opinions)."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the registry study is to demonstrate the clinical utility of the\n      CELLSEARCH\u00ae CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in\n      the United States of Jurisdiction J12 adn JH.  Specifically, the proportion and timing of\n      treatment switching among CTC-tested and untested mBC patients will be described and\n      compared.  Further, the impact of CTC testing on physician behavior with respect to CTC test\n      results will be evaluated via a one-time physician survey.\n\n      This study is IDE-exempt since CELLSEARCH\u00ae CTC Test  is a legally marketed device in the US,\n      and is being used in accordance with its labeling."
        }, 
        "brief_title": "Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Breast Cancer", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients meeting all of the following criteria will be eligible for registry enrollment as\n        cases:\n\n          -  Documented (histologically/pathologically confirmed) mBC diagnosis \u22646 months before\n             registry enrollment by meeting all of the following:\n\n               -  Metastatic Breast Cancer\n\n               -  Diagnosis of Metastases secondary to breast cancer\n\n               -  Date of diagnosis for metastases on or after date of diagnosis for breast cancer\n\n          -  Patient is at least 65 years of age at time of mBC diagnosis\n\n          -  Patient is female\n\n          -  Patient is being actively treated at the cancer center by a physician who uses or\n             plans to use CTC testing on his mBC patients at lease every quarter.\n\n        Exclusion Criteria:\n\n          -  Patient's breast cancer is secondary not primary"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "\"Cases\" of CTC-tested mBC patients being cared for by physicians who routinely (i.e., test\n        at least once every quarter) incorporate CTC testing in their management of mBC patients."
            }
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111031", 
            "org_study_id": "JDX-2014-001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CELLSEARCH", 
            "CTC", 
            "metastatic breast cancer", 
            "mBC", 
            "Novitas", 
            "Registry"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "number_of_groups": "2", 
        "official_title": "Registry to Demonstrate the Clinical Utility of CELLSEARCH\u00ae Circulating Tumor Cell (CTC) Test in Medicare-Eligible Metastatic Breast Cancer Patients - Jurisdiction J12 and Jurisdiction JH Perspective", 
        "overall_contact": {
            "email": "montero2@ccf.org", 
            "last_name": "Alberto Montero, MD"
        }, 
        "overall_official": {
            "affiliation": "Cleveland Clinic Main Campus", 
            "last_name": "Alberto Montero, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The incidence of mBC treatment modifications, calculated by dividing the total number of mBC treatment modifications by the total person-time at risk", 
            "measure": "Incidence of mBC treatment modifications", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111031"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The proportion of patients who experienced mBC treatment modification anytime during the minimum follow-up time between cases and their selected matched controls.  Treatment modification can be any type of change in mBC treatment, including switching, discontinuation, or augmentation of mBC Treatments.", 
                "measure": "mBC treatment modification during the follow-up time between cases and their selected matched controls.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The durations of mBC treatments prior to modification, calculated as the mean (+/- standard deviation [SD]) length of all 'full' treatment courses during follow-up.  Full treatment courses will be defined as courses for which both the start and end dates occurred during follow-up.", 
                "measure": "The durations of mBC treatments prior to modification", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Janssen Diagnostics, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "The Cleveland Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Janssen Diagnostics, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "April 2014"
    }
}